161 related articles for article (PubMed ID: 27699043)
1. Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.
Cebollero A; Puértolas T; Pajares I; Calera L; Antón A
Mol Clin Oncol; 2016 Oct; 5(4):458-462. PubMed ID: 27699043
[TBL] [Abstract][Full Text] [Related]
2. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
Welsh SJ; Corrie PG
Ther Adv Med Oncol; 2015 Mar; 7(2):122-36. PubMed ID: 25755684
[TBL] [Abstract][Full Text] [Related]
3. Bilateral Spontaneous Supraspinatus Tendon Rupture Under Prolonged BRAF/MEK Targeting Treatment in a Melanoma Patient.
Bafaloukos D; Gazouli I; Koutserimpas C; Skarlos PD; Samonis G
Cureus; 2023 Dec; 15(12):e50567. PubMed ID: 38222175
[TBL] [Abstract][Full Text] [Related]
4. Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
Ota T; Okabayashi A; Fukuoka M
Respirol Case Rep; 2021 Oct; 9(10):e0841. PubMed ID: 34484797
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations.
Goldinger SM; Murer C; Stieger P; Dummer R
EJC Suppl; 2013 Sep; 11(2):92-6. PubMed ID: 26217117
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.
Eroglu Z; Ribas A
Ther Adv Med Oncol; 2016 Jan; 8(1):48-56. PubMed ID: 26753005
[TBL] [Abstract][Full Text] [Related]
7. Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma.
Liu JS; Rao S
Exp Hematol Oncol; 2015; 5():9. PubMed ID: 27069772
[TBL] [Abstract][Full Text] [Related]
8. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.
Schreck KC; Grossman SA; Pratilas CA
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466300
[TBL] [Abstract][Full Text] [Related]
9. Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a
Castelli B; Tellini M; Guidi M; Di Nicola M; Giunti L; Buccoliero AM; Censullo ML; Iacono A; Desideri I; Genitori L; Sardi I; Fonte C
Front Oncol; 2024; 14():1359093. PubMed ID: 38774414
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in melanoma treatment - American Society of Clinical Oncology (ASCO) 2012 perspective.
Mackiewicz J; Mackiewicz A
Contemp Oncol (Pozn); 2012; 16(3):197-200. PubMed ID: 23788878
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature.
Büttner R; Gültekin SE; Heydt C; Nogova L; Meemboor S; Kreppel M; Aziz-Heiloun R
Heliyon; 2023 Dec; 9(12):e23206. PubMed ID: 38149213
[TBL] [Abstract][Full Text] [Related]
12.
Abbati F; Altimari A; Corti B; Dika E; Sperandi F; Melotti B
Clin Case Rep; 2021 Apr; 9(4):2200-2204. PubMed ID: 33936664
[TBL] [Abstract][Full Text] [Related]
13. Design, Virtual Screening, Molecular Docking, ADME and Cytotoxicity Studies of 1,3,5-Triazine Containing Heterocyclic Scaffolds as Selective BRAF Monomeric, Homo and Heterodimeric Inhibitors.
Singh AK; Sreelakshmi P; Pathak P; Kumar A; Singh H; Yadav JP; Verma A; Grishina M; Kumar P
Comb Chem High Throughput Screen; 2024 Jan; ():. PubMed ID: 38305404
[TBL] [Abstract][Full Text] [Related]
14. A critical review of RAF inhibitors in BRAF-mutated glioma treatment.
Khoury JE; Wehbe S; Attieh F; Boutros M; Kesrouani C; Kourie HR
Pharmacogenomics; 2024 Jun; ():1-13. PubMed ID: 38884947
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors- A Retrospective Single Center Study.
Friedland R; Glick M; Amitay-Laish I; Toledano H
Dermatology; 2024 May; ():. PubMed ID: 38772345
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study.
Amabile S; Tonella L; Rubatto M; Argenziano G; Babino G; Frascione P; Dika E; Giacomelli L; Parodi A; Quaglino P
Eur J Dermatol; 2022 Feb; 32(1):126-7. PubMed ID: 35153191
[No Abstract] [Full Text] [Related]
17. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR;
N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847
[TBL] [Abstract][Full Text] [Related]
19. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bastholt L; Mortier L; Thomas L; Tahir S; Hauschild A; Hassel JC; Hodi FS; Taitt C; de Pril V; de Schaetzen G; Suciu S; Testori A
N Engl J Med; 2016 Nov; 375(19):1845-1855. PubMed ID: 27717298
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
